MXPA01000066A - Sticking plaster for controlled release of natural interferon - Google Patents
Sticking plaster for controlled release of natural interferonInfo
- Publication number
- MXPA01000066A MXPA01000066A MXPA/A/2001/000066A MXPA01000066A MXPA01000066A MX PA01000066 A MXPA01000066 A MX PA01000066A MX PA01000066 A MXPA01000066 A MX PA01000066A MX PA01000066 A MXPA01000066 A MX PA01000066A
- Authority
- MX
- Mexico
- Prior art keywords
- interferon
- controlled release
- adhesive plaster
- matrix
- support
- Prior art date
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 16
- 102000014150 Interferons Human genes 0.000 title claims abstract description 12
- 108010050904 Interferons Proteins 0.000 title claims abstract description 12
- 229940079322 interferon Drugs 0.000 title claims abstract description 12
- 230000001070 adhesive Effects 0.000 claims abstract description 18
- 239000000853 adhesive Substances 0.000 claims abstract description 18
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
- 230000002940 repellent Effects 0.000 claims description 4
- 239000005871 repellent Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000000414 obstructive Effects 0.000 claims 1
- 230000001681 protective Effects 0.000 claims 1
- 230000003612 virological Effects 0.000 abstract description 3
- 230000003602 anti-herpes Effects 0.000 abstract 1
- 230000035492 administration Effects 0.000 description 6
- 206010047461 Viral infection Diseases 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 208000007514 Herpes Zoster Diseases 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000197 serious side effect Toxicity 0.000 description 2
- 210000004392 Genitalia Anatomy 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
A sticking plaster for controlled release of natural human&agr;-interferon for use in viral therapies, in particular anti-herpes therapies, comprises a thin flexible support and a layered adhesive forming a matrix, a therapeutically effective quantity of the interferon being dispersed in said matrix.
Description
ADHERABLE EMPLASTO FOR CONTROLLED RELEASE OF NATURAL INTERFERON
DESCRIPTION
BACKGROUND OF THE INVENTION
The invention relates to an adhesive plaster for the controlled release of natural interferon for the treatment of viral infections, in particular herpes infections. More particularly, the invention relates to an adhesive plaster for the controlled release of a natural human a-interferon (nHualFN) derived from leukocytic or lymphoblastoid cells, for use in therapies designed to combat genital or labial herpes infections (caused by HSV-1 and HSV-2 viruses), Zoster herpes (HZV), Zoster's neuritis (HZV) and flat warts (HPV). For some time, nHualFN has been used in studies in the field of viral infections and a clearly defined function has been found in recent years in therapies agt chronic and acute viral pathologies, where this is considered to be a "first choice of drug". " Most of the mechanism by which nHualFN acts is known depending on its direct interaction with the target cells and / or the induction of a biological response in the host organism.
The activity of α-interferon as an immunomodulator plays an important role at the organic level in the defense mechanisms agt viral infections. nHualFN is administered parenterally (intravenously, intramuscularly, subcutaneously), orally or topically (ointments and eye washes). Usually the recommended doses are in the order of millions of U. (Units of International Measures) for parenteral administrations, hundreds of thousands of U. for topical preparations and hundreds of U. for oral administrations. These administrations (excluding oral administrations) are prejudged by a series of more or less serious impediments, which make interferon therapy unattractive to patients. The most notable interval of alterations of serious side effects, such as nausea, vomiting or clouding of the senses, which requires the interruption of therapy, to some less significant ones, such as the repetition of problems of the administrations and the unctuousness of the ointments. Furthermore, as a result of the rapid decrease in plasma concentrations of the active ingredient, it is sometimes necessary to resort to overdose in order to achieve satisfactory pharmacological effects, at the risk of generating serious side effects and very high costs in therapy (the therapy is an assistance that is practiced in hospitals or clinics).
Therefore, there is a need for a formulation designed to deal with the aforementioned pathologies when diagnosed with certy, which could allow reducing the dose of nHualFN, without altering its therapeutic effectiveness, and that can be used with a more pleasant method of administration and have more durable and resistant pharmacological effects. The authors of this invention have developed an adhesive plaster for the controlled release of nHualFN which overcomes the drawbacks of known formulations.
BRIEF DESCRIPTION OF THE INVENTION
In fact, the application of an occlusive medication and a controlled release system allows small doses of nHualFN to be administered in the precise place where the viral lesion is located. The msubject of the invention consists of an adhesive plaster for the controlled release of natural human a-interferon for local transcutaneous absorption comprising: a thin inert flexible support comprising an inner side and an outer side; an adhesive with layers on the inner side of said surface to form a matrix; a therapeutically effective amount of said interferon dispersed in the matrix, wherein said support is not a repellent for said matrix, but is a repellent for interferon.
Preferably the support is on a polyurethane base. Preferably, the adhesive comprises substances on an acrylic base. The amounts of nHualFN present are preferably 150 U.I., (International Measuring Units) at 150,000 U.I., more preferably 150 U.I., at 1500 U.I., 15,000 U.I. or 150,000 U.I., in which, in the opinion of the doctors, the dosage would be allowed to vary. Normally the adhesive plaster has an application autonomy of 24 hours. The adhesive plaster should preferably comprise a release strip, such as an inner side protection element, which can be removed at the time of its application, substantially with the same dimensions as the support and preferably manufactured with a central pre-cut. It would be an advantage if the adhesive plaster was available in different forms, to facilitate its use in practice: a square shape and anatomical shapes for the specific parts of the body.DESCRIPTION OF THE PREFERRED MODALITY
The invention will now be described for purposes of illustration, not limitation, with reference to the method used to prepare a 3 x 3 cm adhesive plaster. An adhesive plaster for transcutaneous absorption, for the controlled release of nHualFN derived from leukocytic or lymphoblastoid cells, was prepared as follows: on a plastic support with a square shape and rounded corners, measuring 3 x 3 cm, a matrix is expanded that consists of: an acrylic base, an acrylic acid, etiiénic glycol, a solution of alcohol and water and nHualFN of the desired type and dosage, which in turn is covered with a removable protective layer (liberadora) manufactured with a central precut. Although this description has been described for purposes of illustration, not limitation, according to the preferred forms in which it is to be manufactured, it will be understood that those skilled in the art can make variations and / or modifications in this field, without leaving for this reason the scope of protection.
Claims (5)
1. An adhesive plaster for the controlled release of the natural human a-interferon for transcutaneous obstruction, comprising: a thin flexible support comprising an inner side and an outer side; an adhesive with layers on the inner side of said surface to form a matrix; a therapeutically effective amount of said interferon dispersed in the matrix, wherein said support is not repellent to said matrix, but is repellent to the interferon.
2. The adhesive plaster according to claim 1, further characterized in that said interferon is contained in amounts that are in a range between 150 U.I., and 150,000 U.I.
3. The adhesive plaster according to any of the preceding claims, further characterized in that the interferon is contained in amounts of 150 U.I., 1, 500 U.I., 15,000 U. or 150,000 U.l.
4. The adhesive plaster according to any of the preceding claims further comprises a removable protective element for the internal side of said support, of substantially the same dimensions as the support.
5. - The use of a natural human a-interferon to prepare an adhesive plaster for the controlled release of interferon for transcutaneous absorption, during use in herpes therapies.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01000066A true MXPA01000066A (en) | 2002-07-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2251196T3 (en) | USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C. | |
| EP2533785B1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| EP0911033A3 (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
| US6407125B1 (en) | Pharmacological agent and method of treatment | |
| Risse et al. | Treatment of Verrucous Carcinoma with Recombinant Alfa-lnterferon | |
| WO2014160369A1 (en) | Combined systemic and topical treatment of disordered tissues | |
| MXPA01000066A (en) | Sticking plaster for controlled release of natural interferon | |
| WO1990004977A3 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| US20030206945A1 (en) | Sticking plaster for controlled release of natural interferon | |
| AU756335B2 (en) | Sticking plaster for controlled release of natural interferon | |
| CA2003981C (en) | Pharmaceutical compositions and use thereof in the treatment of psoriasis | |
| EP3672584A1 (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| US9549930B2 (en) | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | |
| US20160030566A1 (en) | Treatment of multiple sclerosis | |
| Cerruti et al. | Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice | |
| Nikkels et al. | Current treatments of muco-cutaneous herpes simplex virus infections | |
| ITRM970298A1 (en) | PATCH WITH CONTROLLED RELEASE OF NATURAL INTERFERON FOR THE TREATMENT OF VIRAL INFECTIONS, PARTICULARLY HERPETIC | |
| US10080761B2 (en) | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 | |
| Rai et al. | Herpes zoster infection of maxillary and mandibular branch: A case report and current trends in management | |
| Edwards | Interferon: promises, disappointments, and tempered optimism | |
| Wiwanitkit | Imiquimod: a new immunomodulatory drug | |
| RU2599038C1 (en) | Use of preparation laennek for treating a disease, associated with impaired immunity, which is a chronic recurrent herpes, atopic dermatitis or psoriasis | |
| RU2162687C2 (en) | Improved medicinal form of interferon inductor | |
| Sacchi | Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection | |
| Ahn et al. | Intralesional Recombinant Alpha-2a Interferon for the Treatment of Patients With Verruca |